505PA randomised, controlled, double blind study of oral methotrimeprazine versus oral haloperidol in patients with cancer and nausea not related to anticancer therapy

Haloperidol is a dopamine receptor blocker commonly used for the treatment of nausea in palliative care patients. Our previous research has shown haloperidol to be an effective antiemetic for nausea not related to anticancer treatment with a response rate at 3 days of 62%. Methotrimeprazine is a broad spectrum phenothiazine that acts at multiple receptor sites to cover a number of possible causes of nausea. Despite the wide use of this drug in palliative care, most of the evidence supporting its use is largely anecdotal. The aim of this study was to compare the antiemetic efficacy of methotrimeprazine with the standard haloperidol in a controlled trial.